Generated by AI
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs. The company’s research is centered on precision medicine approaches that combine chemistry, structural biology, proteomics, and computational methods to identify and optimize novel therapies. Monte Rosa Therapeutics, Inc. operates in the biotechnology sector, where targeted protein degradation is an important area of drug discovery and development.
Website321 Harrison Avenue
Boston, MA, 02118
United States
The latest articles about GLUE.
Monte Rosa Therapeutics is rated a risky Buy, as $580 million cash leaves its pipeline worth about $215 million, with MRT-6160 and MRT-2359 catalysts.
The blended fair value estimate for Monte Rosa Therapeutics has shifted from US$28.00 to US$25.38, reflecting updated assumptions in the latest analyst work. Recent Street commentary links this adjustment to a mix of optimism around MRT-8102 and NEK7 progress, along with caution on execution risk and current valuation, which has led some analysts to trim price targets. Read on to see how these moving pieces fit together and how to track the evolving Monte Rosa Therapeutics story from...
Summary of Oct 1's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Investors talking about GLUE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.